If this is a generalised phenomenon, then a case can be made that in prostate cancer, patients with low CB1IR are sensitive to apoptosis produced by local endocannabinoids (which will be regulated by FAAH and monoacylglycerol lipase), whilst cases with high CB1IR will be insensitive to the local endocannabinoid levels. Here, MGLL is linked to prostate cancer.